Twist Bioscience Corporation (NASDAQ:TWST) on Monday posted first-quarter 2026 results of a loss of 50 cents per share, in line with the Wall Street expectations.
Sales reached $103.70 million, up 17% year over year, beating the consensus of $102.72 million, and the management guidance of $100 million-$101 million.
Adjusted EBITDA loss for the quarter was $13.4 million compared to a loss of $16.3 million a year ago.
The company shipped products to approximately 2,538 customers in the first quarter of 2026, compared to approximately 2,376 a year ago.
Twist shipped approximately 271,000 genes in the quarter compared to approximately 205,000 genes a year ago. The company said more than 50,000 genes were manufactured for data characterization.
Gross margin for the first quarter of fiscal 2026 increased to 52% compared to 48.3% a year ago.
As of December 31, 2025, the company had approximately $198 million in cash, cash equivalents and short-term investments.
“As we …